Effect of Denosumab on Bone Health, Vascular Calcification, and Health-Related Quality of Life in Hemodialysis Patients with Osteoporosis: A Prospective Observational Study
Open Access
- 2 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1462
Abstract
Background: Osteoporosis is common in hemodialysis (HD) patients, contributing to cardiovascular risks. Limited research exists on denosumab’s efficacy in this group. Our study explores denosumab’s effects on bone turnover markers (BTMs) and vascular calcification in chronic kidney disease–mineral bone disorder (CKD-MBD) patients. Methods: In a prospective single-center study, we investigated the effects of denosumab over 2 years on 30 HD patients from a cohort of 185. Annual assessments of bone mineral density (BMD), vascular calcification, and health-related quality of life (HRQL) were conducted and compared with an untreated group. Mineral and bone parameters were analyzed at specific intervals in the treatment group. Results: Denosumab notably raised femoral BMD in the initial year. Most bone turnover markers (BTMs) decreased, except for osteocalcin. Changes in T50 correlated with BTMs. Pre-denosumab supplementation of calcium and vitamin D helped manage mineral imbalances. Post denosumab, parathyroid hormone (PTH) levels increased initially, stabilizing after 3 months. No significant changes occurred in vascular calcification or HRQL. Conclusions: Denosumab exhibited varying effects on BMD improvement, with a stronger impact in the first year that diminished in the second year. Early PTH monitoring was crucial, and extending the administrative period may enhance BMD outcomes compared to the general population.Keywords
Funding Information
- Gil Medical Center, Gachon University (FRD2020-12, NRF-2022R1A2C1091746)
- National Research Foundation of Korea (FRD2020-12, NRF-2022R1A2C1091746)
This publication has 32 references indexed in Scilit:
- Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot studyOsteoporosis International, 2020
- Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort StudyJBMR Plus, 2019
- Chronic kidney disease is associated with low BMD at the hip but not at the spineOsteoporosis International, 2019
- Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled TrialJournal of Bone and Mineral Research, 2019
- The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort studyOsteoporosis International, 2018
- Osteoporosis, bone mineral density and CKD–MBD: treatment considerationsJournal Of Nephrology, 2017
- Safety and efficacy of denosumab in osteoporotic hemodialysed patientsJournal Of Nephrology, 2016
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Quantification of coronary artery calcium using ultrafast computed tomographyJACC, 1990